All In Biotech

Drug Trial Radar · NCT07552987

A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome

A Phase III, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of Intravenous Human Normal Immune Globulin (IGIV) 10% in Adult Patients With Stiff Person Syndrome

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

38

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Kedrion S.p.A.Industry
Sponsor type
Industry
First posted
Apr 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of QIVIGY (Intravenous Human Normal Immune Globulin 10%) compared with placebo in adult participants with stiff person syndrome (SPS).

Conditions

  • Stiff Person Syndrome

Interventions

  • Kedrion IVIg 10%Biological

    Intravenous human normal immunoglobulin (IVIg) 10%

  • Human AlbuminBiological

    Human albumin solution, diluted with saline 0.9% to a final concentration of 0.5% as an intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Timed 25-Foot Walk (T25-FW)Time frame: Baseline to Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.